p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study
1997

p53 Changes in Ovarian Cancer and Their Impact on Treatment

Sample size: 68 publication Evidence: moderate

Author Information

Author(s): F Buttitta, A Marchetti, A Gadducci, S Pellegrini, M Morganti, V Carnicelli, S Cosio, O Gagetti, AR Genazzani, G Bevilacqua

Primary Institution: University of Pisa

Hypothesis

The study investigates the prognostic and predictive role of p53 alterations in ovarian cancer.

Conclusion

Tumours with p53 alterations are less sensitive to chemotherapy and more aggressive than those with functional p53.

Supporting Evidence

  • p53 alterations were found only in invasive ovarian carcinomas, not in low malignant potential tumours.
  • Patients with p53 mutations had a significantly shorter progression-free survival.
  • Only 14% of patients with a complete response to chemotherapy had p53 aberrations.

Takeaway

This study found that changes in a gene called p53 can make ovarian cancer harder to treat and more dangerous.

Methodology

The study analyzed 68 ovarian neoplasms using genetic and immunohistochemical analyses to evaluate p53 alterations.

Limitations

The study's sample size is relatively small, and it focuses only on epithelial ovarian malignancies.

Participant Demographics

Patients aged 41-81 years, median age 59.

Statistical Information

P-Value

p=0.001

Statistical Significance

p<0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication